文献速递血栓与止血

给予concizumab预防治疗猴注射重组FVIIa(rFVIIa)安全,且concizumab不影响rFVIIa在血友病兔中的效力

Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
PubMed 文献 · J Thromb Haemost · 2019-02-20

本研究在体外和体内评估concizumab与rFVIIa联用的效果与安全性。在血友病兔中,concizumab联合rFVIIa对出血无额外作用;在食蟹猴中,高稳态浓度concizumab不影响rFVIIa安全性,病理检查未见血栓。结果支持在concizumab临床试验中使用标准剂量rFVIIa(90 μg kg-1)治疗突破性出血。

要点

  • 在血友病兔中,concizumab联合rFVIIa对出血无额外作用。
  • 高稳态浓度concizumab不影响rFVIIa在食蟹猴中的安全性。
  • 结果支持在concizumab临床试验中使用标准剂量rFVIIa(90 μg kg-1)治疗突破性出血。

核心结论

  • Concizumab在体内不影响rFVIIa的效力或安全性。
  • 结果支持在concizumab临床试验中使用标准剂量rFVIIa(90 μg kg-1)治疗突破性出血。

研究设计与样本

  • 体外研究:将用人FVIII抗体致血友病的人血与递增浓度的concizumab、rFVIIa或两者联合孵育,进行凝血酶生成试验或血栓弹力图。
  • 体内研究:在血友病兔中,于角质层出血前或出血期间给予concizumab、rFVIIa或concizumab联合rFVIIa,测量失血量。
  • 安全性研究:食蟹猴暴露于高稳态浓度concizumab并给予三剂rFVIIa,随后进行全面尸检和组织病理学检查。

主要发现

  • 在致血友病的人血中,concizumab联合rFVIIa的抗凝效果比各自单独反应之和更明显。
  • 在血友病兔中,与单用rFVIIa或单用concizumab相比,concizumab联合rFVIIa对失血量无额外作用。
  • 在食蟹猴中,宏观和微观病理检查未发现血栓或其他过度凝血激活迹象。
  • rFVIIa和concizumab均引起凝血酶-抗凝血酶复合物和D-二聚体浓度升高;同时给药时该效应趋于叠加。

临床怎么用

  • 作者认为,结果支持在concizumab临床试验中使用标准剂量rFVIIa(90 μg kg-1)治疗突破性出血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials Hemophilia patients on concizumab prophylaxis may need rFVIIa to treat breakthrough bleeds. Effect and safety of concizumab + rFVIIa were tested in vitro and in vivo. Concizumab + rFVIIa had no additive effects on bleeding in hemophilic rabbits. High steady-state levels of concizumab did not affect the safety of rFVIIa in cynomolgus monkeys. SUMMARY: Background Concizumab is a monoclonal antibody (mAb) against tissue factor pathway inhibitor (TFPI), currently in clinical development as a subcutaneous prophylactic therapy for hemophilia A/B with and without inhibitors. In patients with inhibitors, the treatment choice for breakthrough bleeding will comprise bypassing agents, e.g. activated recombinant FVIIa (rFVIIa) or activated prothrombin complex concentrates. Objectives To explore the effect and safety of concizumab and rFVIIa when they are simultaneously present. Methods Human blood made hemophilic with a FVIII antibody was spiked with increasing concentrations of concizumab, rFVIIa, or concizumab and rFVIIa in combination, and this was followed by thrombin generation test or thromboelastography. Blood loss in hemophilic rabbits was measured when concizumab, rFVIIa or concizumab + rFVIIa was administered either before or during cuticle bleeding. In a safety study, cynomolgus monkeys were exposed to high steady-state concizumab concentrations and given three doses of rFVIIa, and then subjected to full necropsy and histopathological examination. Results In human blood, concizumab + rFVIIa had more pronounced procoagulant effects under hemophilic conditions than the sum of individual responses. In contrast, concizumab + rFVIIa had no additional effects on blood loss in hemophilic rabbits as compared with rFVIIa or concizumab alone. In cynomolgus monkeys, the macroscopic and microscopic pathological examinations revealed no thrombi or other signs of excessive coagulation activation. Both rFVIIa and concizumab caused increases in thrombin-antithrombin and D-dimer concentrations; this effect tended to be additive with concomitant administration. Conclusions Concizumab did not affect the potency or safety of rFVIIa in vivo. These results support a clinical evaluation of rFVIIa at standard dose (90 μg kg-1 ) to treat breakthrough bleeds in concizumab clinical trials.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lauritzen B, Olling J, Abel KL, et al. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost. 2019. PMID: 30614620. doi:10.1111/jth.14380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。